ADA and anaphylaxis: Symptoms corresponding to the MedDRA term ‘anaphylaxis’ by ADA-positive/negative status and coincident ADA titer were also evaluated for all treatment groups and the frequency of these adverse events will be monitored by routine post-authorization pharmacovigilance.